Metabolic dysfunction–associated steatotic liver disease (MASLD) presents in a spectrum from mild steatosis to advanced fibrosis, cirrhosis and hepatocellular carcinoma, with management decisions shifting dramatically depending on stage. This session explores how obesity treatments intersect with hepatology care, including appropriate screening, lifestyle and pharmacotherapy options tailored to fibrosis stage, and emerging therapies. The lecture will highlight subtle differences in laboratory, imaging, and clinical cues that influence care trajectories across stages.

CME/CE Expiration Date: 4/9/29

*The expiration date listed above is the last day CME/CE credit can be claimed for this specific presentation.